PDCD1 and lung carcinoma: The addition of an anti-Ly6G blocking antibody to anti-PD-1/CTLA-4 therapy effectively reversed treatment resistance and restored CD8+T cell activity in lung cancer models, by targeting Ly6G on neutrophils [186].